Endeavor BioMedicines, Inc. announced that it will issue 20,320,618 series C preferred shares at an issue price of $6.5246 per share for gross proceeds of $132,583,904.20280 on April 19, 2024. The preferred shares are issued at a par value of $0.0001 per share. The company has entered into series C preferred shares purchase agreement with investors in the transaction.

The preferred shares carry non-cumulative fixed dividend value of $0.522 per share and will be convertible in common shares at a fixed conversion price of $6.5246 per share. The company will issue securities pursuant to exemption provided under Regulation D.